Citations

Clear

3138 citation(s) found for "Smith, AM".

Attack adjudication in neuromyelitis optica spectrum disorder: Substantiation of criteria by magnetic resonance imaging and biomarkers in N-MOmentum
Weinshenker, Brian G. , Wingerchuk, Dean M. , Green, Ari , Bennett, Jeffrey L. , Kim, Ho Jin , Pittock, Sean J, Paul, Friedemann , Marignier, Romain , Aktaş, Orhan , She, Dewei, Smith, Michael , Rees, William A. , Patterson, Kristina, Cimbora, Daniel , Katz, Eliezer , Pittock, Sean J. , Kunchok, Amy , Pittock, S J , Green, Ari J , Pittock, Sean J , Marignier, Romain , Cree, Bruce Ac , Bennett, Jeffrey L , Weinshenker, Brian G , Paul, Friedemann , Fujihara, Kazuo , Cutter, Gary , Hartung, Hans‐Peter , Patterson, Kristina R. , Cree, Bruce

Mayo Clinic

Multiple Sclerosis Journal | June 7, 2023 | Volume: 29 | Issue: 8 | Pages: 945-955

10.1177/13524585231172145 | PMID 37282545 Get It

Background: The N-MOmentum trial investigated safety and efficacy of inebilizumab in participants with neuromyelitis optica spectrum disorder (NMOSD). Objective: Evaluate the attack identification process and adjudication committee (AC) performance in N-MOmentum. Methods: Adults ( n = 230) with NMOSD and Expanded Disability Status Scale score ⩽8 were randomized (3:1) to inebilizumab 300 mg or placebo. The randomized controlled period was 28 weeks or until adjudicated attack. Attacks were adjudicated according to 18 predefined criteria. Magnetic resonance imaging (MRI) and biomarker (serum glial fibrillary acidic protein [sGFAP]) analyses were performed. Results: A total of 64 participant-reported neurological events occurred; 51 (80%) were investigator-determined to be attacks. The AC confirmed 43 of the investigator-determined attacks (84%). There was high inter- and intra-AC-member agreement. In 25/64 events (39%) and 14/43 AC-adjudicated attacks (33%), MRI was reviewed during adjudication. Retrospective analysis revealed new domain-specific T1 and T2 MRI lesions in 90% of adjudicated attacks. Increased mean sGFAP concentrations (>2-fold change) from baseline were observed in 56% of adjudicated attacks versus 14% of investigator-determined attacks rejected by the AC and 31% of participant-reported events determined not to be attacks. Conclusion: AC adjudication of NMOSD attacks according to predefined criteria appears robust. MRI lesion correlates and sGFAP elevations were found in most adjudicated attacks.
Outcomes of Kidney Transplantation in Patients That Underwent Bariatric Surgery: A Systematic Review and Meta-analysis
Pencovich, Niv , Kinzelman-Vesely, Elissa A., Sudhindran, Vineeth, Ryan, Randi J. , Kukla, Aleksandra , Diwan, Tayyab S. , Long, Jane J, Long, Jane J. , Smith, Byron H. , Stegall, Mark D.

Mayo Clinic

Transplantation | June 5, 2023 | Volume: 108 | Issue: 2 | Pages: 346-356

10.1097/tp.0000000000004680 | PMID 37271882 Get It

The impact of bariatric surgery (BS) on kidney transplantation (KT) outcomes in patients with obesity remains controversial. We systematically searched MEDLINE, EMBASE, Scopus, Web of Science, and Cochrane Central Register of Controlled Trials for studies reporting outcomes of KT recipients that underwent prior BS. Common/random effects meta-analyses were performed to obtain summary ratios of the postoperative outcomes. Eighteen eligible studies involving 315 patients were identified. Sleeve gastrectomy was the most common BS type (65.7%) followed by Roux-en-Y gastric bypass (27.6%) and gastric banding (4.4%). Across studies that provided the data, the %excess weight loss from BS to KT was 62.79% (95% confidence interval [CI], 52.01-73.56; range, 46.2%-80.3%). The rates of delayed graft function and acute rejection were 16% (95% CI, 7%-28%) and 16% (95% CI, 11%-23%) in 14 and 11 studies that provided this data, respectively. The rates of wound, urinary, and vascular complications following KT were 5% (95% CI, 0%-13%),19% (95% CI, 2%-42%), and 2% (95% CI, 0%-5%), in 12, 9, and 11 studies that provided this data, respectively. Follow-up time after KT was reported in 11 studies (61.1%) and ranged from 16 mo to >5 y. Graft loss was reported in 14 studies with an average of 3% (95% CI, 1%-6%). Four studies that included a comparator group of patients with obesity who did not undergo BS before KT showed comparable outcomes between the groups. We conclude that currently there is a paucity of robust evidence to suggest that pretransplant BS has a major effect on post-KT outcomes. High-quality studies are needed to fully evaluate the impact of BS on KT outcomes.
Rose geranium in sesame oil nasal spray to improve symptoms of nasal vestibulitis: A phase III double blinded randomized controlled trial.
Novotny, Paul J. , Smith, Deanne, Lewis-Peters, Susan E., Steinert, Kimberly O., Dauer, Darcie, O'Connor, Amanda, Thomé, Stephan D. , Register, Terra, Erickson, Marsha K., Friday, Bret Edward Buckley, Loprinzi, Charles L. , Cathcart-Rake, Elizabeth , Giridhar, Karthik V. , O'Connor, Amanda K.

Mayo Clinic

Journal of Clinical Oncology | June 4, 2023 | Volume: 41 | Issue: 16_suppl | Pages: 12114-12114

10.1200/jco.2023.41.16_suppl.12114 Get It

12114 Background: A retrospective study suggested a potential benefit from rose geranium in sesame oil nasal spray for alleviating nasal vestibulitis symptoms in patients (pts) undergoing chemotherapy. Methods: Pts undergoing active chemotherapy who reported moderate or worse nasal symptoms were randomized 1:1 to receive a rose geranium in sesame oil nasal spray (RG) or an isotonic saline nasal spray (IS), administered twice daily for two weeks. Consenting pts completed nasal symptom questionnaires at baseline and then weekly while on treatment. The number and percentage of pts experiencing improvements in their nasal symptoms 2 weeks after initiating the nasal spray, defined as symptoms moderately (2) or very much (3) better on a 7-point global impression of change score (ranging from scores of -3: very much worse, to 3: very much better), was estimated within and then between each randomized arm, using Fisher’s exact test (5% significance level). The estimated odds ratio was determined (95% confidence interval). After 2 weeks, pts initially randomized to IS were allowed to cross-over to RG and completed weekly surveys. Results: 106 pts consented to this study; 43 pts in the RG arm and 41 in the IS arm were evaluable for the primary endpoint. Pts had a mean age of 57.8 (SD 13.9). Demographic characteristics and baseline nasal symptoms were similar between arms. The most prominent baseline nasal symptoms were dryness (36%) and bleeding (35%). Of the 43 evaluable pts who received RG, 67.4% reported improved nasal symptoms, compared with 36.6% of the 41 pts who received IS (p=0.009; Table). On the global impression of change score, pts who received RG had a mean score of 1.93 (SD 1.16), compared to a mean score of 0.98 (SD 1.41) among pts who received IS. Adjusting for potential confounding factors, pts who received RG had a 4.56 odds of responding to the nasal spray, compared with those who received IS (p=0.005). There were no significant differences between pt responses based upon type of nasal symptoms, age, allergies, or gender. Adverse events were sparse and did not differ between arms. 34 pts crossed over to RG after week 2. Among the 29 pts who completed final surveys, 37% reported a response on IS, 79% reported a response on RG. Conclusions: Rose geranium in sesame oil nasal spray significantly improves nasal vestibulitis symptoms among patients undergoing chemotherapy. Clinical trial information: NCT04620369 . [Table: see text]
Regorafenib in older adults with metastatic colorectal cancer: A multi-center, single arm phase II trial.
Badri, Nabeel, Zittel, Jason, Noel, Marcus Smith , Tejani, Mohamedtaki Abdulaziz, Mohile, Supriya G. , Baran, Andrea , Dotan, Efrat , Hubbard, Joleen M. , Hezel, Aram F.

Mayo Clinic

Journal of Clinical Oncology | June 4, 2023 | Volume: 41 | Issue: 16_suppl | Pages: 12047-12047

10.1200/jco.2023.41.16_suppl.12047 Get It

12047 Background: Metastatic colorectal cancer (mCRC) is a leading cause of death, particularly in older adults. Regorafenib (REGO) is an FDA-approved oral multi-kinase inhibitor for refractory mCRC based on the CORRECT trial results, but older adults were underrepresented with a median age of 61 (54–67). This study aimed to evaluate REGO safety in older adults with mCRC and assess the feasibility of using geriatric assessment (GA) to predict toxicity risk. Methods: 27 subjects (PTs) enrolled (median age 73, range 65-85) and started at 120mg of REGO for 21 days of a 28-day cycle with provider discretion to escalate to full dose of 160mg after cycle 1. GA was conducted at enrollment, 4 weeks later, and then every 3 months to monitor for any deterioration. GA assessed 8 geriatric domains (comorbidity, functional status, physical performance, cognition, psychological state, nutrition, medication review, and social support) using validated tools. Primary objective was to assess grade 3-5 toxicity rate, with secondary objectives evaluating REGO efficacy and exploring baseline GA and toxicity risk associations. Kaplan-Meier method was used to estimate median overall survival (OS) and progression-free survival (PFS) from date of consent. Continuous GA measures were compared using non-parametric Wilcoxon rank-sum test, and binary GA measures were compared using Fisher’s exact test. Results: Of 27 PTs enrolled, 15 were male, 12 were female, and 19 identified as white. At baseline, 77.7% of PTs had at least 3 (1-9) GA impairments. Physical performance (80.8%), comorbidity (75%), and cognition (69.2%) were the most prevalent impaired GA domains. 40% required dose reduction by end of cycle 2, and none escalated to full dose. 55% of PTs completed cycle 3. Main reasons for drug discontinuation were disease progression (80%) and toxicity (12%). 74.1% of PTs experienced at least one treatment-related grade 3-4 toxicity. Fatigue (33%), hypertension (30%), and hand-foot syndrome (15%) were the leading grade 3-4 toxicities. Median OS was 5.6 months (95% CI: 3.6-12.2m), and median PFS was 2.8 months (95% CI: 2.5-3.4m). There was no significant difference in baseline GA measures between those who experienced toxicities and those who did not. No statistically significant toxicity risk was associated with any baseline GA impairment. The prevalence of impaired mini-nutritional assessment increased over 4 weeks (58% to 91%, p < 0.01), and median Short Physical Performance Battery (SPPB) scores decreased (7 to 6, p = 0.03). Conclusions: The study found that older adults with mCRC had comparable survival with REGO but experienced high toxicity. This may be ameliorated by recently published step-wise REDOS dosing method and should be considered in older adults with mCRC. The study confirms the feasibility of implementing GA within clinical trials. More data is needed on the role of GA in predicting toxicity with targeted therapies. Clinical trial information: NCT02466009 .
Immune infiltrates in metastatic uveal melanoma liver metastases and associations with clinical outcomes.
Smith, Katherine E. , Jenkins, Sarah M. , Block, Matthew S. , Kottschade, Lisa A. , Montane, Heather N. , Salomão, Diva R. , Javed, Asad , Smith, Katherine E R , Dimou, Anastasios , Dudek, Arkadiusz Z. , Markovic, Svetomir N. , McWilliams, Robert R.

Mayo Clinic

Journal of Clinical Oncology | June 4, 2023 | Volume: 41 | Issue: 16_suppl | Pages: 9538-9538

10.1200/jco.2023.41.16_suppl.9538 Get It

9538 Background: Uveal melanoma has a poor prognosis following metastasis to the liver. Immune checkpoint inhibitors (ICIs) are often utilized in patients with metastatic uveal melanoma (MUM); however, ICIs in MUM have low response rates. We studied the association of immune infiltrates in MUM liver metastases with survival outcomes for all patients, in addition to evaluating if immune infiltrates improve survival for patients treated with ICIs. Methods: We included MUM patients with liver metastases who had pre-treatment liver biopsies available at Mayo Clinic Rochester. Demographics, disease characteristics, treatments, and clinical outcomes were obtained from the electronic medical record. Core biopsies of liver metastases were reviewed for the presence of lymphocytes at interface of the tumor and liver parenchyma, and for tumor-infiltrating lymphocytes (TILs). If TILs were present, then additional immunohistochemistry (IHC) staining was performed for CD3, CD4, CD8, PD1, CD25, and FoxP3. Overall survival (OS) was estimated with the Kaplan-Meier method and compared between groups with Cox proportional hazards regression. Median OS and hazard ratios (HR) were calculated and p-values (p) <0.05 were considered statistically significant. Results: 140 patients with MUM who had pre-treatment liver biopsies were identified. 122 biopsies were evaluable for the presence of lymphocytes, either at the tumor-liver interface, or for TILs. 80/122 (65.6%) biopsies showed presence of any lymphocyte and 27/80 had TILs. 27 biopsies had sufficient tissue for further IHC classification. CD8+ T cells were identified in 27/27 samples, T cell PD1 positivity ≥1% in 4/27 samples, and regulatory T cell markers (CD25 and/or FoxP3) in 18/27 samples. Median OS for the entire cohort was 16 months (mo). Patients still alive at the time of data analysis had at least one year of follow-up available (range 13-124 mo). Univariate analyses (UVA) showed no significant improvement in OS based on the presence of any lymphocytes (HR 1.01, p 0.98), lymphocytes at the tumor-liver interface (HR 1.10, p 0.64), TILs (HR 0.78, p 0.27), >50% CD8+ T cells (HR 0.88, p 0.77), or absence of FoxP3+ T cells (HR 0.68, p 0.40). In the 69 patients treated with ICIs (pembrolizumab, nivolumab, or ipilimumab plus nivolumab), neither the presence of any lymphocytes (HR 1.19, p 0.56) nor TILs (HR 0.68, p 0.24) were associated with an OS benefit. Conclusions: We present a large cohort of patients with MUM where we characterized immune infiltrates in liver metastases and evaluated clinical outcomes. OS did not significantly improve with the presence of any lymphocytes, TILs, CD8+ T cells, or with the absence of FoxP3+ T cells. These results were consistent across all patients whether they were treated with ICIs or not. Our findings suggest that lymphocytes in MUM are functionally dormant and highlights the need for novel immune-activating treatment strategies.
First results from the RETgistry: A global consortium for the study of resistance to RET inhibition in RET-altered solid tumors.
Smith, Katherine E. , Lee, Dae Ho, Nagasaka, Misako , Patel, Jyoti D. , Früh, Martin , Pall, Georg , Uy, Natalie F., Riess, Jonathan W. , Wirth, Lori J. , Yeap, Beow Y., Gainor, Justin F. , Lin, Jessica Jiyeong, Smith, Katherine E R , Cooper, Alissa J. , Drilon, Alexander , Rotow, Julia , Liu, Stephen V. , Gautschi, Oliver , Lee, Dae Ho , Loong, Herbert H. , Pennell, Nathan A , Solomon, Benjamin , Lin, Jessica Jiyeong

Mayo Clinic

Journal of Clinical Oncology | June 4, 2023 | Volume: 41 | Issue: 16_suppl | Pages: 9065-9065

10.1200/jco.2023.41.16_suppl.9065 Get It

9065 Background: Rearranged during transfection ( RET) gene alterations are the oncogenic driver in diverse tumor types, including RET fusions identified in 1-2% of non-small cell lung cancers (NSCLC). While RET-selective tyrosine kinase inhibitors (TKIs) selpercatinib and pralsetinib are effective, acquired drug resistance remains a challenge. Here, we report the initial results from the RETgistry, an international consortium aimed at elucidating mechanisms of resistance to RET TKIs across RET-altered solid tumors. Methods: This was a retrospective analysis performed across 16 institutions. Patients (pts) were eligible if they had advanced solid tumor harboring an oncogenic RET alteration, received ≥1 RET TKI with disease progression, and underwent resistant tumor or liquid biopsy for next-generation sequencing (NGS). Results: A total of 103 time-distinct biopsies (62 tissue, 30 plasma, 11 paired tissue/plasma) were included in analysis, obtained from 88 pts with progression on a RET-selective TKI [selpercatinib (n = 70), pralsetinib (n = 14), selpercatinib and pralsetinib sequentially (n = 4)]. Pts had the following tumor types: 72 NSCLC (69% KIF5B-RET, 21% CCDC6-RET, 10% other RET fusion), 13 medullary thyroid cancer (TC) (54% RET M918T, 46% other RET mutation), and 2 papillary and 1 anaplastic TC (all, RET fusion). Median age was 58 (range, 21-86); 48% were male with 89% never/light smokers. Median duration of RET TKI preceding biopsies [first-line, n = 32 (31%); second-line, n = 42 (41%); third-/greater-line, n = 29 (28%)] was 16.5 months (mos) (95% CI, 14.0-19.6); median PFS was 14.1 mos (95% CI, 9.3-17.0). Resistant biopsies were obtained at median 15.0 mos from TKI initiation (range, 1.8-58.8). Acquired RET mutations were detected in 14 (14%), most common being G810 substitutions in 12 (12%). Potential off-target resistance gene alterations identified in 43 cases (42%) included MET amplification (14%), BRAF V600E or fusion (2%), KRAS gain or mutation (5%), ERBB2 amplification (2%), EGFR amplification (3%), ROS1 fusion (1%), and activating PIK3CA mutation or PTEN loss (4%). No resistant lung cancer biopsy demonstrated small cell transformation. The duration of TKI therapy (HR 0.64, p = 0.11) or PFS (HR 0.75, p = 0.33) did not differ according to the presence of on-target vs off-target resistance. NGS analyses of pre-RET-selective TKI tumors (n = 92) revealed frequent co-occurring alterations in TP53 (29%) and CDKN2A/B (12%). Conclusions: On-target resistance to RET inhibition due to acquired RET mutations was less common than off-target resistance, identified in 14%. The majority of RET TKI resistance is mediated by off-target mechanisms such as bypass receptor tyrosine kinase activation. Further studies are warranted to enable the development of therapeutic strategies to address resistance in pts with RET-altered tumors. The RETgistry accrual and data analyses continue.
Alliance A022104/NRG-GI010: A randomized phase II trial testing the efficacy of triplet versus doublet chemotherapy to achieve clinical complete response in patients with locally advanced rectal cancer—The Janus Rectal Cancer trial.
Hong, Theodore S. , Philip, Philip Agop, Nelson, Garth D. , Baghdadi, Tareq Al, Shergill, Ardaman , Hall, William A. , Smith, J. Joshua , Dasari, Arvind , Shi, Qian , García‐Aguilar, Julio , Sanoff, Hanna K. , George, Thomas J. , Yothers, Greg , Alese, Olatunji B. , O’Reilly, Eileen M. , Meyerhardt, Jeffrey A. , Horvat, Natally , Romesser, Paul B.

Mayo Clinic

Journal of Clinical Oncology | June 4, 2023 | Volume: 41 | Issue: 16_suppl | Pages: TPS3640-TPS3640

10.1200/jco.2023.41.16_suppl.tps3640 Get It

TPS3640 Background: Recent data have demonstrated that in locally advanced rectal cancer (LARC), a total neoadjuvant therapy (TNT) approach improves compliance with chemotherapy and increases rates of tumor response compared to neoadjuvant chemoradiation (CRT) alone. They further indicate that the optimal sequencing of TNT involves consolidation (rather than induction) chemotherapy to optimize complete response rates. Data, largely from retrospective studies, have also shown that patients (pts) with clinical complete response (cCR) after neoadjuvant therapy may be managed safely with the watch and wait approach (WW) instead of preemptive total mesorectal resection (TME). However, the optimal consolidation chemotherapy regimen to achieve cCR has not been established, and a randomized clinical trial has not robustly evaluated it as a primary endpoint. Collaborating with a multidisciplinary oncology team and pt groups, we designed this NCI-sponsored study of chemotherapy intensification to address these issues and to drive up cCR rates, to provide opportunity for organ preservation and improve quality of life for pts. Methods: In this Alliance for Clinical Trials in Oncology randomized phase II trial (1:1), up to 312 pts with microsatellite stable LARC, clinical stage T4N0, any T, N+ or T3N0 requiring abdominoperineal resection or coloanal anastomosis and distal margin within 12 cm of anal verge will be enrolled. Stratification factors include tumor stage (T4 vs T1-3), nodal stage (N+ vs N0) and distance from anal verge (0-4; 4-8; 8-12 cm). Pts will be randomized to receive neoadjuvant long course CRT (LCRT) followed by consolidation doublet (mFOLFOX6 or CAPOX) or triplet chemotherapy (mFOLFIRINOX) for 4 months. LCRT in both arms involves 4500 cGy in 25 fractions over 5 weeks (w) + 900 cGy boost in 5 fractions with a fluoropyrimidine (capecitabine preferred). Pts will undergo assessment 8-12 w post-TNT completion for the primary endpoint of cCR per previously validated criteria and recommended WW and surveillance if cCR is achieved or TME if an incomplete response is noted. Secondary objectives include time-to event outcomes (disease-free and overall survival, organ preservation time and time to distant metastasis) and adverse effects. Statistical power, based on cCR, incorporates a one-sided alpha = 0.048 and power = 90% yielding 312 patients (156 per arm). Biospecimens including archival tumor tissue, matched / normal blood samples and serial rectal MRI will be collected for exploratory correlative research. This study, activated in late 2022, is open across the NCTN and is actively recruiting. Support: U10CA180821, U10CA180882, U24 CA196171; https://acknowledgments.alliancefound.org . U10CA180868 (NRG); U10CA180888 (SWOG); Clinicaltrials.gov ID: NCT05610163 Clinical trial information: NCT05610163 .
Recurrence patterns among patients with sinonasal mucosal melanoma: A multi‐institutional study
Pandrangi, Vivek C. , Mace, Jess C. , Adappa, Nithin D. , Beswick, Daniel M. , Chang, Eugene H. , Fung, Nicholas , Hong, Michelle , Johnson, Brian J. , Kohanski, Michael A. , Lee, Jivianne T. , Nabavizadeh, Seyed Ali , Obermeyer, Isaac P. , Adappa, Nithin D. , Smith, Timothy L. , Suh, Jeffrey D. , Wang, Marilene B. , Beswick, Daniel , Johnson, Brian Jake , Kshirsagar, Rijul S , Kuan, Edward C , Smith, Timothy L , Snyderman, Carl H , Wang, Eric W , Choby, Garret , Abiri, Arash , Adappa, Nithin D. , Eide, Jacob G. , Fung, Nicholas, Kshirsagar, Rijul S. , Le, Christopher H. , Pinheiro‐Neto, Carlos , Choby, Garret , Geltzeiler, Mathew

Mayo Clinic

International Forum of Allergy & Rhinology | June 2, 2023 | Volume: 13 | Issue: 12 | Pages: 2156-2164

10.1002/alr.23204 | PMID 37265013 Get It

AbstractObjectiveTo evaluate recurrence patterns and survival after recurrence among patients with sinonasal mucosal melanoma (SNMM).MethodsThis was a multi‐institutional retrospective review from seven U.S. institutions of patients with SNMM from 1991 to 2022. Recurrence was categorized as local, regional, distant, or multifocal. Kaplan‐Meier tests were used to evaluate disease‐free survival (DFS), overall survival (OS), and post‐recurrence survival (PRS) reported with standard errors (SE) and log‐rank testing used for comparison. Cox‐regression was further used, with hazard ratios (HR) and 95% confidence intervals (CI) reported.ResultsAmong 196 patients with SNMM, there were 146 patients with recurrence (74.5%). Among all patients, 60‐month DFS (SE) was 15.5% (2.9%), 60‐month OS (SE) was 44.7% (3.7%), mean age ± standard deviation at diagnosis was 69.7 ± 12.5 years, and 54.6% were female. In 26 patients who underwent primary treatment of the neck, 60‐month DFS did not differ from no treatment (p > 0.05). Isolated distant recurrence was most common (42.8%), followed by local (28.3%), multifocal (20.7%), and regional recurrence (8.3%). Among patients with regional recurrence in the neck, there was no 60‐month PRS benefit for patients undergoing salvage neck dissection or radiation (p > 0.05). Among patients with distant recurrence, only immunotherapy was associated with improved 12‐month PRS (HR = 0.32, 95% CI = 0.11–0.92, p = 0.034), and no treatment group was associated with improved 24‐ or 60‐month PRS (p > 0.05).ConclusionSNMM is associated with a high recurrence rate and poor survival. Primary treatment of the neck was not associated with reduced recurrence, and immunotherapy for treatment of distant recurrence was associated with increased 12‐month PRS.
Race-free estimated glomerular filtration rate equation in kidney transplant recipients: development and validation study
Raynaud, Marc , Awadhi, Solaf Al, Divard, Gillian , Dubourg, Laurence , Mariat, Christophe , Prié, Dominique , Pernin, Vincent , Larson, Timothy S., Bikbov, Boris , Ruggenenti, Piero , Ibrahim, Hassan N. , Nielsen, Marie Bodilsen , Matas, Arthur J. , Nankivell, Brian J. , Benjamens, Stan , Pol, Robert A. , Bakker, Stephan J. L. , Jouven, Xavier , Legendre, Christophe , Wadei, Hani M. , Dürrbach, Antoine , Vincenti, Flavio , Lefaucheur, Carmen , Loupy, Alexandre , Wadei, Hani M , Al-Awadhi, Solaf , Divard, Gillian , Jurić, Ivana , Lombardi, Yannis , Bašić‐Jukić, Nikolina , Aubert, Olivier , Masson, Ingrid , Quintrec, Moglie Le , Stegall, Mark D. , Mesnard, Laurent , Kamar, Nassim , Smith, Byron H. , Remuzzi, Giuseppe , Bentall, Andrew , Loupy, Alexandre

Mayo Clinic

BMJ | May 31, 2023 | Volume: 381 | Issue: No issue available | Pages: e073654

10.1136/bmj-2022-073654 | PMID 37257905 Get It

Abstract Objective To compare the performance of a newly developed race-free kidney recipient specific glomerular filtration rate (GFR) equation with the three current main equations for measuring GFR in kidney transplant recipients. Design Development and validation study Setting 17 cohorts in Europe, the United States, and Australia (14 transplant centres, three clinical trials). Participants 15 489 adults (3622 in development cohort (Necker, Saint Louis, and Toulouse hospitals, France), 11 867 in multiple external validation cohorts) who received kidney transplants between 1 January 2000 and 1 January 2021. Main outcome measure The main outcome measure was GFR, measured according to local practice. Performance of the GFR equations was assessed using P 30 (proportion of estimated GFR (eGFR) within 30% of measured GFR (mGFR)) and correct classification (agreement between eGFR and mGFR according to GFR stages). The race-free equation, based on creatinine level, age, and sex, was developed using additive and multiplicative linear regressions, and its performance was compared with the three current main GFR equations: Modification of Diet in Renal Disease (MDRD) equation, Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) 2009 equation, and race-free CKD-EPI 2021 equation. Results The study included 15 489 participants, with 50 464 mGFR and eGFR values. The mean GFR was 53.18 mL/min/1.73m 2 (SD 17.23) in the development cohort and 55.90 mL/min/1.73m 2 (19.69) in the external validation cohorts. Among the current GFR equations, the race-free CKD-EPI 2021 equation showed the lowest performance compared with the MDRD and CKD-EPI 2009 equations. When race was included in the kidney recipient specific GFR equation, performance did not increase. The race-free kidney recipient specific GFR equation showed significantly improved performance compared with the race-free CKD-EPI 2021 equation and performed well in the external validation cohorts (P 30 ranging from 73.0% to 91.3%). The race-free kidney recipient specific GFR equation performed well in several subpopulations of kidney transplant recipients stratified by race (P 30 73.0-91.3%), sex (72.7-91.4%), age (70.3-92.0%), body mass index (64.5-100%), donor type (58.5-92.9%), donor age (68.3-94.3%), treatment (78.5-85.2%), creatinine level (72.8-91.3%), GFR measurement method (73.0-91.3%), and timing of GFR measurement post-transplant (72.9-95.5%). An online application was developed that estimates GFR based on recipient’s creatinine level, age, and sex ( https://transplant-prediction-system.shinyapps.io/eGFR_equation_KTX/ ). Conclusion A new race-free kidney recipient specific GFR equation was developed and validated using multiple, large, international cohorts of kidney transplant recipients. The equation showed high accuracy and outperformed the race-free CKD-EPI 2021 equation that was developed in individuals with native kidneys. Trial registration ClinicalTrials.gov NCT05229939 .